Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8689660 | 0.87 | GABRA1 (0.48) | EGFRPPARGPPARDPPARABAZ2B | |
| SCHEMBL8687615 | 0.85 | MCL1 (0.46) | MCL1EGFROXER1PPARGBAZ2B | |
| SCHEMBL4616719 | 0.81 | KDM4E (0.50) | KDM4EL3MBTL1KMT2AMAPTTSHR | |
| SCHEMBL8687160 | 0.79 | ACLY (0.62) | EGFRKDM4EKMT2AACLY | |
| SCHEMBL27779044 | 0.79 | RAB9A (0.44) | MCL1PPARGKMT2AMAPTGFER | |
| SCHEMBL4616361 | 0.79 | MCL1 (0.53) | MCL1OXER1 | |
| SCHEMBL9956776 | 0.78 | KDM4E (0.52) | KDM4EL3MBTL1KMT2AMAPTRAB9A | |
| SCHEMBL9240535 | 0.78 | EGFR (0.42) | MCL1EGFROXER1BAZ2BKDM4E | |
| SCHEMBL9231968 | 0.77 | EGFR (0.47) | EGFRKDM4EL3MBTL1KMT2ATSHR | |
| SCHEMBL4615149 | 0.77 | SRC (0.47) | PPARGPPARAKDM4EL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-0550111-B1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-04-14 | — | — | EP | disclosed |
| US-5856349-A | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-01-05 | — | — | US | disclosed |
| US-5852046-A | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| US-5652254-A | TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS | SANOFI, S.A. (FR) | 1997-07-29 | — | — | US | disclosed |
| US-5563163-A | TREATMENT OF DEGENERATIVE DISEASES | STERLING WINTHROP, INC. (US) | 1996-10-08 | — | — | US | disclosed |
| CN-1118347-A | Benzotoudened 5-ringneterocycl, preparation and phamaceutical and diagnostic use of same | HOECHST AG (DE) | 1996-03-13 | — | — | CN | disclosed |
| US-5488062-A | 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0639573-A1 | Benzocondensed five membered heterocycles, process of their preparation, their use as drug, as diagnostic means and pharmaceuticals containing it | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-22 | — | — | EP | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | MCL1 4564/4885EGFR 2885/4885OXER1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.